Articles filed under 'HPV'
Researchers are trying to determine whether the virus that causes cold sores can somehow play a role in bringing on Alzheimer’s disease in later years. A study published recently in the journal Neurobiology of Aging is looking at interaction between the ApoE-4 gene and herpes as a risk factor for the brain-robbing disease.
According to one researcher at the University of Manchester, Alzheimer’s patients who have the ApoE-4 form of the gene contain more herpes DNA in brain regions than others without that version of the gene. The team found that the herpes virus infiltrates brain cells and is associated with cellular tangles and amyloid plaques in Alzheimer’s patients.
The oral herpes virus (herpes simplex 1), known to infect 80% of Americans, hides in the body’s nerves in its predominately latent phase. An outbreak is rarely triggered by factors such as stress, fatigue, or sunlight. HPV1 then becomes active, damaging cells and causing cold sores.
Scientists have long known that the ApoE-4 gene is a player in Alzheimer’s, but the idea that it can work in concert with the herpes virus is new. A group at the University of Rochester Medical Center recently found that this particular gene causes a fertile environment for herpes in the brain.
One theory is that the body’s immune response against herpes somehow damages the brain. The damage can be worse in those with the ApoE-4 copy of the gene than in those with another form of the gene, such as ApoE-2 or ApoE-3. No research is conclusive at this point.
In 2006, the Manchester research team published a study that showed inflammation to be the earliest change detected in a brain affected by Alzheimer’s disease, before the hallmark plaques or tangles appear and long before any behavioral changes are seen. Such inflammation can be a byproduct of the body’s immune system fighting an infection.
Much research is being conducted in the field of Alzheimer’s Disease. It is hoped that one day it may be prevented, especially if treatment begins in the early stages before symptoms become obvious.
Source: Medical News TODAY
January 27th, 2007
A three-year study of 82 women volunteers, initially virgins, at the University of Washington showed that after becoming sexually active, they reduced their chances of contracting human papilloma virus (HPV) by 70% when partners always used a condom.
Women in the study kept journals of their sexual practices and were checked for HPV every four months with swabs of the cervix and other genital areas. They noted whether there was any genital contact before using the condom.
HPV can cause cervical cancer, genital warts, vaginal, vulvar, anal and penile cancers. It is the most common sexually transmitted disease (STD), infecting about 80% of young women within five years after becoming sexually active. HPV is frequently killed by the immune system, but in some women, the virus causes lesions that can become cancerous.
Worldwide, about 500,000 develop cervical cancer and nearly 300,000 die of it annually. In the U.S., some 3,500 women die of it each year.
Known to prevent AIDS and pregnancy, condoms are recently found to give significant protection against HPV, as well. Their use can also provide protection against gonorrhea, Chlamydia and herpes in men and women.
In early June, the U.S. government approved the first vaccine against HPV. If given to young women before they become sexually active, it could prevent them from ever contracting the virus.
Sources: CNN.com, San Francisco Chronicle; 6/22/06
Technorati Tags: Sexual Health, HPV, Condoms
June 28th, 2006
In a unanimous vote, an FDA advisory committee recently voted to endorse the safety and effectiveness of Gardasil. The new vaccine developed by Merck Pharmaceuticals has been shown to protect women from two types of the human papilloma virus, responsible for about 70% of cervical cancer cases. The potential to cut worldwide deaths from the disease is huge.
HPV is the most common sexually transmitted disease, affecting an estimated 50% of sexually active adults. Each year, cervical cancer kills 290,000 women worldwide. About 3,500 of the annual deaths occur in the U.S., where many women have the opportunity for early detection through regular pap smears. Treatment for precancerous lesions and early cervical cancer greatly reduce mortality rates in the U.S..
Gardasil is the first vaccine known to prevent cervical cancer. If approved by the FDA, the Merck vaccine could be the biggest advance in eradicating cervical cancer since the pap test was introduced decades ago.
Merck recommends using the vaccine in females age 9 to 26. Gardasil can be most effective if young girls are vaccinated before they became sexually active. The vaccine is not intended to take the place of regular cervical screening.
The FDA is expected to endorse the use of the vaccine at a June meeting. If approval is given, a national Advisory Committee on Immunization Practices will decide whether to advocate routine vaccination with Gardasil.
Source: CNN.com
More Information
May 30th, 2006
A new cancer vaccine still in the experimental stages appears to provide protection against several strains of cervical cancer for up to five years. Results of a study of 1,100 women to test the efficacy of the vaccine Cervarix were published in the April 6 issue of The Lancet.
At 4.5 years, the vaccine was still protecting all women who received the vaccine, according to study author Dr. Diane Harper. Cervarix is designed to protect against human papilloma virus (HPV) types 16 and 18, responsible for about 70 percent of cervical cancers.
The vaccine seems to offer similar protection against HPV types 45 and 31, which can also trigger cervical cancer, the second most common malignant disease in women worldwide. Spread by sexual contact, human papilloma viruses are the main cause of cervical cancer.
Women taking part in the study received either three doses of Cervarix or a placebo. Those who got the vaccine had no more long-term side effects than those getting the placebo injection.
Cervarix is yet to be approved for general use on the market. Preliminary results show from antibody levels tested that protection remains unchanged nearly five years later. Further investigation of the new vaccine will take place before the vaccine is approved for widespread use.
A similar vaccine called Gardasil is awaiting approval by the U.S. Food and Drug Administration (FDA). Gardasil is thought to protect against HPV 16 and 18 as well as HPV 6 and 11, which account for about 90% of genital warts.
Gardasil could be on the market later this year and would likely be given to women in their late teens or early 20s. Cervical cancer is often diagnosed at a younger age than any other cancers.
Source: MedicineNet.com
Also see the latest news and discoveries for Gardasil
April 17th, 2006